脲原体属抗生素耐药性:值得关注的问题
综述聚焦脲原体属抗生素耐药性,指出其固有耐药导致治疗选择极为有限,新生儿感染中大环内酯类和氟喹诺酮类耐药株增加可能导致泛耐药和无法治疗的状况。强调准确药敏测定的要求,并指出商业试剂盒在耐药报告中的局限性。
要点
- 脲原体固有耐药导致治疗选择有限,新生儿中耐药株增加可能致泛耐药。
- 商业试剂盒可用于初筛,但耐药报告须用国际标准化方法。
- 高滴度或混有微小脲原体的样本常导致假耐药结果。
核心结论
- 脲原体属耐药性上升值得关注,新生儿感染中大环内酯类和氟喹诺酮类耐药可能导致泛耐药和无法治疗的状况。
研究设计与样本
- 综述文献中脲原体属抗菌药物耐药性的报告,并讨论药敏测定要求和商业试剂盒的局限性。
主要发现
- 脲原体属因独特生理学而具有高水平固有耐药,治疗选择极为有限,常限于大环内酯类或罕用氟喹诺酮类。
- 新生儿感染中大环内酯类和氟喹诺酮类耐药株的增加可能导致泛耐药。
- 耐药模式差异显著,新生儿人群中高水平耐药的影响提示需要持续监测。
- 高滴度样本或混有微小脲原体的样本常规给出假耐药结果。
临床怎么用
- 商业试剂盒可用于初始抗生素敏感性测定和筛查,但耐药报告必须采用国际标准化方法。
- 需注意高滴度或混有微小脲原体的样本可能导致假耐药结果。
局限性
- 未来报告需要确定 underlying AMR 机制,并判断耐药扩展是自发突变、移动元件上耐药基因传播还是耐药克隆的选择和扩增。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is growing global concern regarding the rise of antibiotic-resistant organisms. Many of these reports have focused on various Gram-positive and Gram-negative pathogens, with little attention to the genus Ureaplasma. Ureaplasma spp. are associated with numerous infectious diseases affecting pregnant women, neonates and the immunocompromised. Treatment options are extremely limited due to high levels of intrinsic resistance resulting from the unique physiology of these organisms and further restricted in cases of the developing fetus or neonate, often limiting therapeutic options to predominantly macrolides or rarely fluoroquinolones. The increasing presence of macrolide- and fluoroquinolone-resistant strains among neonatal infections may result in pan-drug resistance and potentially untreatable conditions. Here, we review the requirements for accurate measurement of antimicrobial susceptibility, provide a comprehensive review of the antimicrobial resistance (AMR) for Ureaplasma species in the literature and contextualize these results relative to some investigators' reliance on commercial kits that are not CLSI compliant when determining AMR. The dramatic variation in the resistance patterns and impact of high levels of AMR amongst neonatal populations suggests the need for continued surveillance. Commercial kits represent an excellent tool for initial antibiotic susceptibility determination and screening. However, AMR reporting must utilize internationally standardized methods, as high-titre samples, or Mycoplasma hominis-contaminated samples routinely give false AMR results. Furthermore, there is a requirement for future reports to determine the underlying AMR mechanisms and determine whether expanding AMR is due to spontaneous mutation, transmission of resistance genes on mobile elements or selection and expansion of resistant clones.
引用
- Beeton ML, Spiller OB. Antibiotic resistance among Ureaplasma spp. isolates: cause for concern? J Antimicrob Chemother. 2016. PMID: 27798207. doi:10.1093/jac/dkw425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。